PMID- 32075584 OWN - NLM STAT- MEDLINE DCOM- 20200513 LR - 20231113 IS - 1471-2334 (Electronic) IS - 1471-2334 (Linking) VI - 20 IP - 1 DP - 2020 Feb 19 TI - Adverse events in Chinese human immunodeficiency virus (HIV) patients receiving first line antiretroviral therapy. PG - 158 LID - 10.1186/s12879-020-4878-2 [doi] LID - 158 AB - BACKGROUND: Although the global human immunodeficiency virus (HIV) epidemic has improved significantly due to antiretroviral treatment (ART), ART-related adverse events (AEs) remain an issue. Therefore, investigating the factors associated with ART-related AEs may provide vital information for monitoring risks. METHODS: A prospective cohort study was conducted among adult patients (aged 18 years or older) with HIV who received Tenofovir (TDF) + Lamivudine (3TC) + Efavirenz (EFV) as first-line ART regimens. All AEs during the first 12 months of therapy were recorded. Logistic regression analysis was used to identify variables associated with AEs. RESULTS: Four hundred seventy-four patients receiving TDF+ 3TC+ EFV ART regimens between March 2017 and October 2017 were included in the study analysis. Among them, 472 (99.6%) experienced at least one AE, 436 (92.0%) patients experienced at least one AE within 1 month of treatment, 33 (7.0%) between one and 3 months of treatment, and three (0.6%) patients after 3 months of treatment. The most commonly reported AE was nervous system (95.6%) related, followed by dyslipidemia (79.3%), and impaired liver function (48.1%). Patients with baseline body mass index (BMI) greater than 24 kg/m(2) (adjusted OR 1.77, 95%CI 1.03-3.02), pre-existing multiple AEs (adjusted OR 2.72, 95%CI 1.59-4.64), and pre-existing severe AEs (adjusted OR 5.58, 95%CI 2.65-11.73) were at increased odds of developing a severe AE. Patients with baseline BMI greater than 24 kg/m(2) (adjusted OR 2.72, 95%CI 1.25-5.89) were more likely to develop multiple AEs. CONCLUSION: The incidence of ART-related adverse events over a 12-month period in China was high. Baseline BMI greater than 24 kg/m(2), pre-existing multiple AEs, and pre-existing severe AEs were shown to be independent risk factors for developing a severe AE. FAU - Dai, Lili AU - Dai L AD - Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. FAU - Su, Bin AU - Su B AD - Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. FAU - Liu, An AU - Liu A AD - Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. FAU - Zhang, Hongwei AU - Zhang H AD - Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. FAU - Wu, Hao AU - Wu H AD - Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. FAU - Zhang, Tong AU - Zhang T AD - Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. FAU - Shao, Ying AU - Shao Y AD - Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. FAU - Li, Jianwei AU - Li J AD - Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. FAU - Ye, Jiangzhu AU - Ye J AD - Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. FAU - Bai, Shaoli AU - Bai S AD - Department of Infectious Disease, Lanzhou Pulmonary Hospital, Lanzhou, 730046, China. FAU - Guo, Xiaoling AU - Guo X AD - Department of Infectious Disease, Lanzhou Pulmonary Hospital, Lanzhou, 730046, China. FAU - Sun, Lijun AU - Sun L AD - Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. guoqingliang0524@163.com. LA - eng GR - 2018ZX10721102-003-003/National 13th Five-Year Grand Program on Key Infectious Disease Control/ GR - 2018ZX10302-102/National 13th Five-Year Grand Program on Key Infectious Disease Control/ GR - 2017ZX10202102-005-003/National 13th Five-Year Grand Program on Key Infectious Disease Control/ GR - 2017ZX10202101-004-001/National 13th Five-Year Grand Program on Key Infectious Disease Control/ GR - 81601795/National Natural Science Foundation of China/ GR - 81772165/National Natural Science Foundation of China/ GR - 81571973/National Natural Science Foundation of China/ PT - Journal Article DEP - 20200219 PL - England TA - BMC Infect Dis JT - BMC infectious diseases JID - 100968551 RN - 0 (Alkynes) RN - 0 (Anti-HIV Agents) RN - 0 (Benzoxazines) RN - 0 (Cyclopropanes) RN - 2T8Q726O95 (Lamivudine) RN - 99YXE507IL (Tenofovir) RN - JE6H2O27P8 (efavirenz) SB - IM MH - Adolescent MH - Adult MH - Alkynes MH - Anti-HIV Agents/*adverse effects/therapeutic use MH - Antiretroviral Therapy, Highly Active/*adverse effects MH - Benzoxazines/adverse effects/therapeutic use MH - Body Mass Index MH - China/epidemiology MH - Cyclopropanes MH - Dyslipidemias/chemically induced/epidemiology MH - Female MH - HIV Infections/*drug therapy MH - Humans MH - Incidence MH - Lamivudine/adverse effects/therapeutic use MH - Male MH - Middle Aged MH - Preexisting Condition Coverage MH - Prospective Studies MH - Tenofovir/adverse effects/therapeutic use MH - Young Adult PMC - PMC7031902 OTO - NOTNLM OT - Adverse events OT - Antiretroviral therapy OT - China OT - HIV COIS- The authors declare that they have no conflict of interests. EDAT- 2020/02/23 06:00 MHDA- 2020/05/14 06:00 PMCR- 2020/02/19 CRDT- 2020/02/21 06:00 PHST- 2019/09/10 00:00 [received] PHST- 2020/02/12 00:00 [accepted] PHST- 2020/02/21 06:00 [entrez] PHST- 2020/02/23 06:00 [pubmed] PHST- 2020/05/14 06:00 [medline] PHST- 2020/02/19 00:00 [pmc-release] AID - 10.1186/s12879-020-4878-2 [pii] AID - 4878 [pii] AID - 10.1186/s12879-020-4878-2 [doi] PST - epublish SO - BMC Infect Dis. 2020 Feb 19;20(1):158. doi: 10.1186/s12879-020-4878-2.